X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Divis Laboratories Fact Sheet, Divis Laboratories Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Divis Laboratories Fact Sheet   (DIVI)

Here is the latest financial fact sheet of Divis Laboratories. For more details, see the Divis Laboratories quarterly results and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.

DIVIS LABORATORIES Price History

Price Rs 1,085.5
Mkt Cap Rs m 288,152
Vol '000 59.9
P/E X 33.1
P/CF X 24.3
EPS (TTM) Rs 32.8
% ch % 1.1
No. of shares m 265.47
% ch week % -3.0
% ch 1-mth % -1.1
% ch 12-mth % 47.8
52 week H/L Rs 1,220.0/605.8
(As on Jul 18, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DIVIS LABORATORIES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
DIVIS LABORATORIES EQUITY SHARE DATA
High Rs1,2331,4591,8812,4841,222 
Low Rs7529051,217918784 
Sales per share (Unadj.) Rs161.6190.8234.7142.3153.1 
Earnings per share (Unadj.) Rs45.458.364.242.439.9 
Diluted earnings per shareRs22.729.132.142.439.9 
Cash flow per share (Unadj.) Rs51.265.274.446.944.6 
Dividends per share (Unadj.) Rs15.0020.0020.0010.0010.00 
Adj. dividends per shareRs7.5010.0010.0010.0010.00 
Dividend yield (eoy) %1.51.71.30.61.0 
Book value per share (Unadj.) Rs188.4223.3288.0161.7201.8 
Adj. book value per shareRs94.2111.6144.0161.7201.8 
Shares outstanding (eoy) m132.73132.73132.73265.47265.47 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x6.16.26.612.06.6 
Avg P/E ratio x21.920.324.140.125.1 
P/CF ratio (eoy) x19.418.120.836.322.5 
Price / Book Value ratio x5.35.35.410.55.0 
Dividend payout %33.134.331.223.625.0 
Avg Mkt Cap Rs m131,735156,887205,599451,525266,266 
No. of employees `000NANA8.79.59.7 
Total wages/salary Rs m1,9772,3252,9043,6124,687 
Avg. sales/employee Rs ThNMNM3,571.83,983.14,175.0 
Avg. wages/employee Rs ThNMNM333.0381.0481.5 
Avg. net profit/employee Rs ThNMNM976.41,187.41,089.3 
DIVIS LABORATORIES INCOME DATA
Net Sales Rs m21,44825,32131,14937,76440,643 
Other income Rs m448706447974749 
Total revenues Rs m21,89726,02731,59638,73841,392 
Gross profit Rs m8,15210,14511,65214,17414,460 
Depreciation Rs m7709211,3601,1821,233 
Interest Rs m1821193823 
Profit before tax Rs m7,8129,90910,72113,92813,953 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,7922,1762,2062,6713,349 
Profit after tax Rs m6,0207,7338,51511,25810,604 
Gross profit margin %38.040.137.437.535.6 
Effective tax rate %22.922.020.619.224.0 
Net profit margin %28.130.527.329.826.1 
DIVIS LABORATORIES BALANCE SHEET DATA
Current assets Rs m18,64122,56427,72430,27040,105 
Current liabilities Rs m5,5456,2744,5605,1956,595 
Net working cap to sales %61.164.374.466.482.5 
Current ratio x3.43.66.15.86.1 
Inventory Days Days142134136117119 
Debtors Days Days87104878581 
Net fixed assets Rs m12,12113,66315,23116,99819,995 
Share capital Rs m266266266531531 
"Free" reserves Rs m24,73529,36337,95842,40253,043 
Net worth Rs m25,00629,63438,22342,93353,574 
Long term debt Rs m21161150 
Total assets Rs m31,38837,10543,82949,02161,585 
Interest coverage x439.9482.0577.4369.5618.4 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.70.70.80.7 
Return on assets %19.220.919.523.017.3 
Return on equity %24.126.122.326.219.8 
Return on capital %31.333.528.132.526.1 
Exports to sales %86.789.284.385.30 
Imports to sales %21.820.023.922.925.2 
Exports (fob) Rs m18,60222,57526,24432,1980 
Imports (cif) Rs m4,6815,0697,4428,65410,259 
Fx inflow Rs m18,78922,61726,31732,27035,384 
Fx outflow Rs m4,7965,1837,5888,77510,399 
Net fx Rs m13,99317,43418,72923,49624,985 
DIVIS LABORATORIES CASH FLOW
From Operations Rs m 4,800 5,568 8,263 10,379 11,493 
From Investments Rs m -2,545 -3,052 -5,208 -4,064 -11,372 
From Financial Activity Rs m -2,308 -2,485 -3,030 -6,311 -93 
Net Cashflow Rs m -53 31 25 3 28 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 0.0%
Indian inst/Mut Fund 11.8%
FIIs 19.0%
ADR/GDR 0.0%
Free float 17.2%
Shareholders 31,796
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 7-1-77/E/1/303, Divi Towers, Dharam Karan Road, Ameerpet, Hyderabad-16
E-MAIL cs@divislaboratories.com WEB www.divislaboratories.com
TELEPHONE (040) 2378 6300 FAX (040) 2378 6460
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR P. V. R. K. Nageswara Rao & Co.
CHM: Murali K. Divi (MD) COMP SEC: P. V. Lakshmi Rajani YEAR OF INC: 1990 BSE CODE: 532488 FV (Rs): 2 DIV YIELD (%): 0.9

More Pharmaceuticals Company Fact Sheets:   ELDER PHARMA  CADILA HEALTHCARE  WYETH LTD  GLENMARK PHARMA  BIOCON LTD  

Compare DIVIS LABORATORIES With:   ELDER PHARMA  CADILA HEALTHCARE  WYETH LTD  GLENMARK PHARMA  BIOCON LTD  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)

Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.

Views on news

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - TEVA PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS